We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · May 20, 2021

Sustainable Responses in Metastatic Melanoma Patients After Elective Discontinuation of Anti–PD1-Based Immunotherapy

European Journal of Cancer


Additional Info

European Journal of Cancer
Sustainable Responses in Metastatic Melanoma Patients With and Without Brain Metastases After Elective Discontinuation of Anti-PD1-Based Immunotherapy Due to Complete Response
Eur. J. Cancer 2021 May 01;[EPub Ahead of Print], F Dimitriou, A Zaremba, C Allayous, KC Kähler, CL Gerard, L Festino, S Schäfer, F Toussaint, L Heinzerling, JC Hassel, PA Ascierto, O Michielin, A Hauschild, C Lebbe, E Livingstone, E Ramelyte, PF Cheng, R Dummer, J Mangana

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading